Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Public ClinicalTrials.gov record NCT00490776. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor
Study identification
- NCT ID
- NCT00490776
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Interventions
- Panobinostat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2007
- Primary completion
- Aug 31, 2009
- Completion
- Sep 21, 2009
- Last update posted
- Aug 17, 2021
2007 – 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham/ The Kirklin Clinic | Birmingham | Alabama | 35233 | — |
| UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology | Los Angeles | California | 90095 | — |
| University of Colorado Health Sciences Center/Anschutz Cancer Pavillion | Aurora | Colorado | 80010 | — |
| Florida Academic Dermatology Centers | Miami | Florida | 33136 | — |
| Medical College of Georgia | Augusta | Georgia | 30912 | — |
| Rush Presbyterian Hospital/St. Luke's Medical Center | Chicago | Illinois | 60612 | — |
| St. Louis University Cancer Cennter | St Louis | Missouri | 63110 | — |
| Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| NYU Clinical Cancer Center | New York | New York | 10016 | — |
| Our Lady of Mercy Medical Center/Comprehensive Cancer Center | The Bronx | New York | 10466 | — |
| Wake University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| University of Oklahoma-Tulsa | Tulsa | Oklahoma | 74104 | — |
| Craig Okada | Portland | Oregon | 97239 | — |
| University of Pittsburg Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| The Jones Clinic | Germantown | Tennessee | 38138 | — |
| MD Anderson Cancer Center/University of Texas | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109-102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00490776, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00490776 live on ClinicalTrials.gov.